Bovine Respiratory Disease Treatment Market Continues To Grow Owing To the Demand from Various Cattle Owners to Protect Their Cattle and Supply High-Quality Meat to Consumers

 

Bovine respiratory disease treatment is a condition caused by exposure to contaminated tapeworm segments, which are found in raw or semi-raw dairy products and meat. Exposure to live or raw eggs can cause an infection and should be avoided to prevent worsening the situation. Treatment is relatively simple and consists of identifying infected eggs, removing them from the body, and then treating the infection through the administration of antibiotics. This process requires daily applications of a medicated spray and is effective for mild to moderate cases. More severe cases may require a course of intravenous antibiotics followed by a vapor rub, which helps to loosen the congested and hard lumpy mucus that often accompanies the disease. Topical corticosteroids may also be prescribed in severe cases to relieve symptoms and reduce the number of fluids in the lungs.

Market Dynamics                                  

The main driving factor influencing the bovine respiratory disease treatment market is the rapid increase of this disease. The rapid expansion of the cattle population and changing environmental conditions are estimated to propel the market growth. According to a report by Beef Cattle Research Council, Bovine respiratory diseases result in 65-80% of morbidity and 45-75% of mortality rates in the cattle yards in the U.S. Moreover, rising awareness among the consumers related to healthy meat consumption, new environmental protection rules, and animal health monitoring practices are expected to boost the growth of the bovine respiratory disease treatment market.

However, the absence of awareness related to meat consumption in developing nations is the main restraining factor hindering market growth. Few complications are related to Bovine respiratory disease treatment. Animals that are suffering from bovine respiratory diseases sometimes show signs of weight loss, depression, mucopurulent or purulent nasal discharge, cough, and increased body temperature. The diagnosis after identifying these physical symptoms is tough owing to the similarities of the symptoms to other bacteria-caused diseases. Hence this factor is estimated to hinder the market growth.

This market is distributed in five regions that include North America, Europe, Asia-Pacific, Middle East, and Africa, and Latin America. Among these North America is estimated to hold a significant share of the bovine respiratory disease treatment market owing to the number of factors such as clusters of a bovine animal, increase in bovine respiratory diseases, and extensive expenditure on bovine health awareness. In the U.S. heavy amount of meat is consumed which comprises mainly of poultry and beef, and this factor is expected to drive the Bovine respiratory disease treatment market in the region. For instance, according to the North American Meat Institute, in 2019, the U.S. total consumption of beef amounted to approximately US$ 27.3 billion. The Asia Pacific is estimated to witness significant growth in the Bovine respiratory disease treatment market owing to the presence of a large number of animals and increasing awareness related to animal welfare in the region.

Competitive Analysis

Key players in the bovine respiratory disease treatment market include Bimeda Animal Health, Vetoquinol, Elanco, Boehringer Ingelheim GmbH, Virbac Group, Merck & Co., Inc., Bayer AG, and Zoetis Inc.

In September 2018, Boehringer Ingelheim GmbH introduced Bovalto Respi Intranasal, which is a new respiratory vaccine used in the treatment against viruses such as Bovine Respiratory Syncytial Virus (BSRV) and Parainfluenza 3 Virus in cattle. Likewise, in April 2018, VIDO - InterVac announced about developing a new vaccine that can protect cattle in Africa from bovine pleuropneumonia (CBPP).